On the heels of the rescission of the Fintiv guidance memorandum, the U.S. Patent and Trademark Office has again reshaped the PTAB’s approach to discretionary denials. On March 26, 2025, the Acting Director issued a new memorandum that fundamentally changes how the PTAB will handle inter partes review and post grant review petitions

Now, all IPR and PGR institution decisions will be decided in two stages: (1) a threshold analysis focused solely on discretionary denials related to parallel proceedings or issues already decided by the Patent Office; and (2) decisions regarding institution based on the merits of the petition itself, but only if the petition survives step 1.

This shift gives patent owners a clearer and potentially earlier path to avoiding PTAB review altogether—without ever having to debate the merits of the petition.

This isn’t the first time the PTAB’s discretionary denial practices have drawn attention. A 2022 PTAB memorandum was issued after pushback from patent challengers—particularly in cases where the parallel litigation was fast-tracked for trial in district court like those in the Eastern District of Texas. The 2022 guidance signaled that median times-to-trial and particularly meritorious petitions would be given stronger weight to potentially overcome a discretionary denial. This guidance gave petitioners a lifeline, especially for strong petitions.

But that lifeline is diminished. On February 28, 2025, that 2022 memorandum was rescinded.  With the March 26, 2025 memorandum, the PTAB has doubled down, creating a bifurcated procedure elevating the discretionary decision over the merits of a petition.  

In accordance with the new memorandum, parties will file opposing briefs addressing only discretionary considerations under 35 U.S.C. §§ 314 and 325 concerning denial of institution. The PTAB will then issue a decision as to whether it will deny institution under its discretion, prior to even considering the merits of the petition itself. If the PTAB chooses not to exercise discretion to deny institution, it will then go on to examine the merits of the challenge and issue an institution decision accordingly.

Patent owners will likely find this bifurcated approach to be a rebalancing of the PTAB playing field. Indeed, by addressing purely discretionary issues first, meritorious petitions may be denied based on a pending district court litigation that is set for trial. Patent owners may be drawn to rocket docket jurisdictions, such as the Eastern District of Texas, known to set early trial dates—regardless of whether those dates hold. Under the factors for discretionary denial, a scheduled trial date that occurs before the final written decision (which is approximately 18 months after a petition is filed) weighs against institution.

On the other hand, the new PTAB processes appear to create a steeper uphill battle for patent challengers. They must now clear an early procedural hurdle just to get the PTAB to consider the merits of their case. With no guarantee that even a strong petition will be reviewed, patent challengers will be forced to accelerate the completion and filing of IPR petitions (potentially even prior to the service of a district court complaint in some instances) and weigh their options as to whether a PTAB petition is justified in the face of likely discretionary denial and to increase the odds of success having the petition heard on the merits.

The USPTO says this bifurcated approach is “temporary in nature” and is based on the PTAB’s current workload. These recent PTAB guidance memoranda have already altered the landscape under which patent challengers choose to file petitions. Our team will be monitoring any additional guidance, PTAB institution decisions, and trends indicating how the PTAB’s new approaches are impacting discretionary denials. If you have questions about how this ruling could impact your patent portfolio or patent litigation strategy, we’re here to help.

Photo of Joseph Drayton Joseph Drayton

A first-chair trial lawyer, Joe Drayton has represented some of the nation’s most prominent companies across a wide array of industries in all facets of intellectual property (IP) litigation before both state and federal courts, as well as the International Trade Commission and…

A first-chair trial lawyer, Joe Drayton has represented some of the nation’s most prominent companies across a wide array of industries in all facets of intellectual property (IP) litigation before both state and federal courts, as well as the International Trade Commission and American Arbitration Association.

Joe has more than two decades of experience specializing in both domestic and international intellectual property and complex commercial disputes, including patent, trade secrets, copyright, trademark and trade dress and false advertising across diverse industries. He also counsels clients in all aspects of IP acquisition, transfer, protection and enforcement.

Joe is a trusted advisor for several corporate executives and a national leader in the legal community. He is regularly recognized as one of the top lawyers in the U.S., having consistently been named to the IAM Patent 1000 list. Most recently, Joe received the C. Francis Stadford Award by the National Bar Association, the highest award bestowed by the association that is given to a member whose leadership, integrity, legal skills and devotion have inspired colleagues and contributed greatly to the legal profession. A longtime bar leader, Joe served as the 76th president of the National Bar Association and is also a former vice president and Board chair of the New York City Bar Association.

Photo of Erik Milch Erik Milch

Erik Milch is a partner in the Litigation Department and a member of the Intellectual Property, Patent Law and Trials group.

Erik brings more than 20 years of experience litigating in key jurisdictions across the U.S., as well as before the International Trade…

Erik Milch is a partner in the Litigation Department and a member of the Intellectual Property, Patent Law and Trials group.

Erik brings more than 20 years of experience litigating in key jurisdictions across the U.S., as well as before the International Trade Commission and the U.S. Patent and Trademark Office. As a first-chair trial lawyer, Erik litigates complex matters involving medical devices, life sciences instrumentation, pharmaceuticals, electrical and computer technology, and consumer products. He regularly counsels clients in a range of industries in connection with patent procurement, development of patent portfolios, patent licensing, valuation of patent portfolios in business transactions and transactional diligence.

Erik has extensive experience in all aspects of patent litigation from pre-filing through appeal, including enforcement of patents against competitors and defense of patent infringement allegations. His technical background includes microfluidics, lab automation, optical imaging instruments, wound closure, surgical instrumentation, orthopedics, autoinjectors, tissue resection and sealing, pharmaceuticals, haptic feedback systems, computer software, consumer products, fluid mechanics applications, automotive engines and mechanical and electrical components, aerospace propulsion and control systems, weapons systems, and telecommunications.

Erik has been consistently recognized in Chambers USA and IAM Patent 1000 for his significant expertise in patent litigation. He was also recognized as a “Top Lawyer” by The Washingtonian.

Prior to pursuing a legal career, Erik earned a bachelor’s degree in mechanical engineering from Georgia Tech, where he developed a deep appreciation for cutting-edge technology and its potential to drive progress. His background in engineering equips him with a unique ability to comprehend intricate technical concepts. This enables him to effectively navigate the intricate world of patent litigation, combining his legal skills with technical know-how to provide comprehensive and strategic counsel to his clients.

In addition to his academic accomplishments, Erik served as an officer in the United States Navy. His military background instilled in him a strong sense of discipline, leadership, perseverance, and attention to detail; qualities that continue to guide him in his legal practice.

Photo of Elizabeth Shrieves Elizabeth Shrieves

Elizabeth (Beth) Shrieves is an associate in the Litigation Department and a member of the Intellectual Property and Patent Law groups. Beth has experience litigating in numerous federal district courts across the United States, as well as before the Federal Circuit, U.S. Patent…

Elizabeth (Beth) Shrieves is an associate in the Litigation Department and a member of the Intellectual Property and Patent Law groups. Beth has experience litigating in numerous federal district courts across the United States, as well as before the Federal Circuit, U.S. Patent and Trademark Office, and International Trade Commission. Beth’s experience covers a wide variety of products and technology involving software and applications, medical devices and technology, electrical hardware, telecommunications, supercapacitors, automotive engines, weapon systems, and consumer products. She has counseled clients throughout all stages of litigation, including both plaintiff and defense work, from pre-suit investigation, initial pleadings, discovery, trial, and through appeal.

Beth graduated from George Mason University School of Law where she earned her J.D., Magna Cum Laude. Prior to earning her law degree, she received a bachelor’s degree from Wake Forest University where she also graduated Magna Cum Laude. Beth also previously worked as a paralegal where she gained a deeper understanding of the nuances of commercial litigation.